Combination Therapy With Fecal Microbiota Transplantation and Vedolizumab for Induction of Remission in Ulcerative Colitis: An Open-Label Pilot Study
Lay Summary In our pilot study, combining weekly fecal transplantation with vedolizumab for induction of remission in ulcerative colitis patients who had previously failed other advanced therapy did not result in any adverse events; however, recruitment was limited, likely due to changes in prescribing patterns in this patient population.
Authors
- John K. Marshall (ORCID: https://orcid.org/0000-0002-0523-9032)
- Michael G. Surette (ORCID: https://orcid.org/0000-0003-0086-4995)
- Neeraj Narula (ORCID: https://orcid.org/0000-0002-1536-8436)
- Jaiminkumar Patel
- Dina Kao (ORCID: https://orcid.org/0000-0002-6096-0586)
- Paul Moayyedi (ORCID: https://orcid.org/0000-0002-3616-9292)
- Saad A. Syed (ORCID: https://orcid.org/0000-0002-5504-9173)
Institutions
- University of Alberta (CA)
- Population Health Research Institute (CA)
- Institut de Recherche en Santé Digestive (FR)
- McMaster University (CA)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-11-04
- DOI
- https://doi.org/10.1093/ibd/izaf284
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- McMaster University
- University of Alberta
- Takeda Canada